A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids

Neuroreport
K VaddadiP Dingjan

Abstract

Huntington's Disease (HD) is a serious dominantly inherited neurodegenerative disorder for which there are no current treatments. Open label and animal studies have suggested that highly unsaturated fatty acids (HUFAs) may be beneficial. Seventeen patients with HD were entered into a randomised, placebo-controlled, double blind trial of HUFA therapy. Patients were assessed on the Rockland-Simpson Dyskinesia Rating Scale (RSDRS) and the Unified Huntington's Disease Rating Scale (UHDRS). On the RSDRS and the UHDRs motor scale patients on HUFA treatment improved while those on placebo deteriorated, with a significant difference between the two groups on the RSDRS. A similar trend was noted on the UHDRS functional performance scales. Little change was seen on the neuropsychology scales. There were no treatment-related adverse events. This is the first time that a significant improvement has been noted in a randomised trial in HD. The results are consistent with open label observations; a second placebo-controlled study in end-stage patients, and a study in a transgenic mouse model of HD.

References

Aug 8, 1979·Psychopharmacology·G M SimpsonG Gardos
Nov 1, 1984·British Journal of Pharmacology·B CostallR J Naylor
Mar 1, 1996·Movement Disorders : Official Journal of the Movement Disorder Society
Aug 1, 1996·Prostaglandins, Leukotrienes, and Essential Fatty Acids·A NilssonL Wilhelmsen

❮ Previous
Next ❯

Citations

Mar 12, 2003·Current Treatment Options in Neurology·Salil Manek, Mark F. Lew
Jun 11, 2008·Neuromolecular Medicine·S C Dyall, A T Michael-Titus
Apr 13, 2004·International Clinical Psychopharmacology·Raphael M BonelliHans P Kapfhammer
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Steven M Hersch, Robert J Ferrante
Jan 4, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Jia Yi LiPatrik Brundin
Apr 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Brian Hallahan, Malcolm R Garland
Jan 30, 2007·Expert Opinion on Pharmacotherapy·Raphael M Bonelli, Peter Hofmann
May 21, 2009·Expert Opinion on Emerging Drugs·Sarah L Mason, Roger A Barker
Jun 17, 2008·Progress in Neurobiology·Sabien van NeervenJörg Mey
Oct 15, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Charles S VenutoKarl Kieburtz
Dec 16, 2010·Journal of Cellular and Molecular Medicine·Dénes ZádoriLászló Vécsei
Sep 13, 2014·Movement Disorders : Official Journal of the Movement Disorder Society·Liliana Menalled, Daniela Brunner
Oct 12, 2004·Nutrition·Undurti N Das, Krishna S Vaddadi
Mar 14, 2007·Brain Research Bulletin·Harald Murck, Mehar Manku
Mar 2, 2016·Nutritional Neuroscience·Adriana Morales-MartínezFrancisca Pérez-Severiano
Apr 23, 2004·Expert Opinion on Pharmacotherapy·Raphael M Bonelli, Peter Hofmann
Aug 9, 2005·Expert Opinion on Therapeutic Targets·Anthony J Hannan
Jun 26, 2012·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Gunter P EckertWalter E Muller
May 17, 2007·Cell Transplantation·Shilpa RamaswamyJeffrey H Kordower
Dec 9, 2017·American Journal of Medical Genetics. Part a·Audrey S Dickey, Albert R La Spada
Mar 1, 2018·Molecular Psychiatry·Hélèna L DenisFrancesca Cicchetti
Jun 17, 2006·International Review of Psychiatry·Krishna VaddadiJohn Waddington
Jul 10, 2009·The Cochrane Database of Systematic Reviews·Tiago MestreCristina Sampaio
Mar 20, 2018·The Cochrane Database of Systematic Reviews·Karla Soares-WeiserHanna Bergman
Jan 12, 2019·Neurotoxicity Research·Musthafa Mohamed EssaMohammed Akbar
Jul 8, 2020·Antioxidants·José Bono-YagüeRafael Pascual Vázquez-Manrique
Jun 17, 2006·International Review of Psychiatry·Gregor E BergerG Paul Amminger
Oct 27, 2018·Movement Disorders Clinical Practice·Tiago A MestreUNKNOWN Members of the MDS Committee on Rating Scales Development

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.